EP0031 Poster British Thoracic Oncology Group {{ vc_btn: title=Download+as+PDF&style=custom&custom_background=%23000066&custom_text=%23ffffff&shape=round&size=lg&align=center&css=.vc_custom_1773221293678%7Bpadding-top%3A+15px+%21important%3B%7D&link=url%3Ahttps%253A%252F%252Fellipses.life%252Fwp-content%252Fuploads%252F2026%252F03%252FEP0031_BTOG-2026-poster.pdf%7Ctarget%3A_blank }} About Ellipses Pharma Limited Ellipses Pharma is a global drug development company based in London, focused on accelerating the development of cancer treatments through an innovative drug development model that combines unbiased vetting to de-risk initial asset selection with an uninterrupted funding flow to minimise [...]

Ellipses in-licenses first-in-class B7H3 Antibody Drug Conjugate from China London, January 19, 2026 Ellipses Pharma Limited (“Ellipses”), a clinical-stage oncology drug development company with a pipeline of innovative programmes, announced that it has entered into a collaboration and licence agreement with Innolake Biopharm Co. Ltd (“Innolake”) to develop a clinical stage first-in-class antibody drug conjugate [...]

Next-generation Selective RET Inhibitor EP0031(A400) accepted for review by regulatory authorities in China Ellipses Pharma (“Ellipses”), a global drug development company focused on accelerating the development of cancer treatments through an innovative drug development model, announced today that its partner, Kelun Biotech, has had a new drug application (NDA) for the next generation selective RET [...]

EP0031 Poster ASCO 2025 {{ vc_btn: title=Download+larger+version&style=custom&custom_background=%23000066&custom_text=%23ffffff&shape=round&size=lg&align=center&css=.vc_custom_1749190534045%7Bpadding-top%3A+15px+%21important%3B%7D&link=url%3Ahttps%253A%252F%252Fellipses.life%252Fwp-content%252Fuploads%252F2025%252F06%252FEP0031_Poster_ASCO_2025.pdf%7Ctarget%3A_blank }} About Ellipses Pharma Limited Ellipses Pharma is a global drug development company based in London, focused on accelerating the development of cancer treatments through an innovative drug development model that combines unbiased vetting to de-risk initial asset selection with an uninterrupted funding flow to minimise the time [...]